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The nucleotide uridine trisphosphate (UTP) released to the extracellularmilieu acts as a signalingmolecule via activation of specific
pyrimidine receptors (P2Y). P2Y receptors are G protein-coupled receptors expressed in many cell types. These receptors mediate
several cell responses and they are involved in intracellular calciummobilization.We investigated the role of the prostanoid PGE
2
in
P2Y signaling in mouse embryonic fibroblasts (MEFs), since these cells are involved in different ontogenic and physiopathological
processes, among them is tissue repair following proinflammatory activation. Interestingly, Ca2+-mobilization induced by UTP-
dependent P2Y activation was reduced by PGE
2
when this prostanoid was produced by MEFs transfected with COX-2 or when
PGE
2
was added exogenously to the culturemedium.This Ca2+-mobilizationwas important for the activation of differentmetabolic
pathways in fibroblasts. Moreover, inhibition of COX-2 with selective coxibs prevented UTP-dependent P2Y activation in these
cells. The inhibition of P2Y responses by PGE
2
involves the activation of PKCs and PKD, a response that can be suppressed after
pharmacological inhibition of these protein kinases. In addition to this, PGE
2
reduces the fibroblast migration induced by P2Y-
agonists such as UTP. Taken together, these data demonstrate that PGE
2
is involved in the regulation of P2Y signaling in these
cells.
1. Introduction
P2 receptors are purinergic receptors selective for adenosine
5󸀠-trisphosphate (ATP), adenosine 5󸀠-diphosphate (ADP),
uridine 5󸀠-trisphosphate (UTP), and uridine 5󸀠-diphosphate
(UDP). These nucleotides act as extracellular signaling mol-
ecules and exert their activity by binding to and activating
specific membrane receptors, designed P2 receptors [1, 2].
There are two families of P2 receptors structurally distinct:
P2X ionotropic ion channel receptors and P2Y metabotropic
G protein-coupled receptors [3–5]. Currently, seven P2X
subtypes and eight P2Y receptor subtypes are recognized,
including receptors that are sensitive to pyrimidines as well
as to purines [6]. Receptors for purine and pyrimidine nucle-
otides are involved in many neuronal as well as nonneu-
ronalmechanisms, including short-termpurinergic signaling
such as neurotransmission, neuromodulation, neurosecre-
tion, immune responses, inflammation, platelet aggregation,
and vasodilatation, and long-term purinergic signaling of cell
proliferation, differentiation, motility, and death in develop-
ment and regeneration [7].
At present, there are eight accepted P2Y receptors: P2Y1,
P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and P2Y14 [8, 9].
The metabotropic receptors, coupled to phospholipase C
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(PLC), can be activated by different nucleotides, depending
on the P2Y receptors and the species studied [10]. In the
aftermath of nucleotide release to the extracellular medium
these receptors are stimulated leading to an intracellular
increase in diacylglycerol (DAG) and inositol trisphosphate
(IP3) followed by a release of calcium from intracellular stores
[11, 12]. These receptors are widely distributed in several
cell types; their existence in fibroblasts was first reported by
Okada et al. [13]. Fibroblasts respond to inflammation and
damage, being involved in the repair phase following tissue
damage, or in other pathological circumstances, such as ath-
erogenesis [14].
Prostaglandin E
2
(PGE
2
) is an important chemical medi-
ator generated from arachidonic acid via the cyclooxygenase
pathway. The various biological effects of PGE
2
are mediated
by four receptors called E-type prostanoid receptors (EP1 to
EP4), which are G protein-coupled membrane receptors [15].
EP1 leads to mobilization of intracellular calcium. This tran-
sient change in intracellular Ca2+ alters the activity of many
proteins, including several isoforms of PKC.Therefore, PGE
2
evokes Ca2+- and PKC-mediated effects in cells expressing
EP1 [16]. EP2 and EP4 signaling generates increased intra-
cellular cyclic AMP (cAMP) levels, whereas EP3 leads to a
reduction in intracellular cAMP levels [17, 18]. However, in
addition to EP-mediated effects, PGs may exert other EP-
independent actions, for example, through the purinergic
signaling [19, 20].
Taken together, both signaling pathways generate DAG
and IP3, promoting Ca2+ mobilization. This alteration may
affect the activity of several proteins, such as PKCand, indeed,
previous work have described that the signaling of G pro-
tein-coupled receptors is regulated by mechanisms involv-
ing protein kinases such as PKC [21]. Although it has been
shown that PGE
2
is a potent inhibitor of the purinergic sig-
naling mediated by some purinergic receptors [19, 20], less
is known about the underlying cross-talk between PGs and
P2 signaling as a mechanism integrating inflammation and
the presence of extracellular nucleotides. In the present work
we have investigated this interplay between PGs and P2
receptors in mouse embryonic fibroblasts (MEFs). Our data
extend previous work in macrophages and suggest that this
communication between the two pathways is functional in
MEFs adding a new piece of knowledge to understand how
fibroblast activity may be regulated by these dual signaling
pathways.
2. Materials and Methods
2.1. Reagents. UTP, ionophores, and standard reagents were
from Sigma-Aldrich (St Louis, MO, USA). DFU was from
Merck (Rahway, NJ, USA). Prostaglandin E
2
was from Cay-
man Chemical (Ann Arbor, MI, USA). Go¨6976, Go¨6983,
Go¨6850, and inhibitors of standard signaling pathways were
from Calbiochem (San Diego, CA, USA). Fura-2/AM was
from Invitrogen (Carlsbad, CA, USA). Cytokines were from
PeproTech (London, UK). Antibodies against P2Y2, P2Y4,
and P2Y6 receptors were from Alomone Labs (Jerusalem,
Israel) and other antibodies were from Santa Cruz Biotech
(Santa Cruz, CA, USA), from Cell Signaling (Danvers,
MA, USA), or from the sources previously described [22].
Reagents for electrophoresis were from Bio-Rad (Hercules,
CA, USA) and Sigma-Aldrich. Tissue culture dishes were
from Falcon (Lincoln Park, NJ, USA) and culture media were
from Invitrogen.
2.2. Animals. COX-2 wild type (WT) and COX-2-deficient
mice, with a mixed background 129SV and C57BL/6, were
obtained from the Jackson Laboratory. Mice were housed
under 12 h light/dark cycle and food and water were provided
ad libitum. Animals were cared for according to a protocol
approved by the Ethical Committee of our institution (follow-
ing directive 2010/63/EU of the European Parliament).
2.3. Preparation of Mouse Embryonic Fibroblasts (MEFs), Cell
Culture, and MEFs Immortalization. MEFs were prepared
from E14.5 embryos from WT and COX-2-deficient mice.
Briefly, femalemice were euthanized by CO
2
at 14.5 after con-
ception. Using scissors, the abdomen was opened and the
embryos were isolated with their yolk sacs intact. The yolk
sac was removed and retained for genotyping. The head and
internal organs of each embryo were discarded.The dissected
embryo was passed through an 18G needle to disperse the
cells [23]. MEFs were cultured (2 × 106 cells per 60mm dish
or in 12-multiwell plates at a density of 2 × 105 cells/well) in
Dulbecco’sModifiedEagle’sMedium (DMEM) supplemented
with 10% fetal bovine serum (FBS), 100 U/mL penicillin,
100 𝜇g/mL streptomycin at 37∘C, and 5% CO
2
[24, 25].
COX-2+/+ and COX-2−/− primary MEFs were transfected
with a SV40 large T-antigen expression vector using Lipo-
fectamine 2000 (Invitrogen), according to manufacturer’s
instructions, to obtain immortalized MEF cell line (referred
to as MEFs WT, KO, or KI-carrying the COX-2 transgene).
2.4. Transfection. To ectopically express COX-2, COX-2-
deficient MEFs were transiently transfected with 4 𝜇g of
plasmidDNA (per well in a 6-well plate) using Lipofectamine
2000 reagent following the instructions of the supplier.
Briefly, MEF cells at 70% confluence were exposed for 6–
16 h to Lipofectamine reagent containing pPyCAGIP-COX-
2 or control vector pPyCAGIP. At the end of this period,
the transfection media were replaced with fresh medium
containing 10% FBS. COX-2 expression was determined by
Western blot.
2.5. Determination of PGE
2
by Enzyme Immunoassay. PGE
2
accumulation was measured in the culture medium. For the
assay, WT and KI (COX-2-deficient MEFs overexpressing
COX-2)MEFs were plated in 6-well plates at a density of 1.5 ×
106 cells/well in 2mL DMEM and treated in the absence or
presence of LPS (200 ng/mL) plus cytokines (IFN-𝛾, TNF-
𝛼, and IL-1𝛽, 20 ng/mL) for 18 h at 37∘C. The culture super-
natants were centrifuged at 12,000×g for 5min and PGE
2
levels were determined by specific immunoassay (DetectX
Prostaglandin E
2
, Arbor Assays, Ann Arbor MI, USA),
according to the manufacturer’s instructions.
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2.6. Calcium Dynamic Analysis. MEFs attached to coverslips
were incubated in Locke’s solution as previously described
[20]. The effect of purinergic receptor agonists was assayed
at near-maximal effective concentrations (100 𝜇MUTP) [26].
In other studies, 5𝜇M PGE
2
was applied for 5min before
nucleotides perfusion in the presence of prostanoids. When
pharmacological inhibitors were used, they were preincu-
bated at the indicated concentrations and for the required
times as specified in the text and figure legends and kept
during prostanoid incubation and/or purinergic agonist
stimulation. After dual excitation at 340 and 380 nm the
fluorescence was recorded and analyzed. Background signals
were subtracted from each wavelength and the F
340
/F
380
ratio
was calculated [27]. Alternatively, in some cases (indicated
in the corresponding figure legends), calcium mobilization
was measured using the nonratiometric Fluo-4 direct probe
(Invitrogen), following the instructions of the supplier. In this
case, the changes in fluorescence were measured in a fluores-
cence microscope (Observer Z1, Plan Apochromat objective,
Zeiss) equipped with a Cascade1K camera, analyzed using
the Axiovision 4.8 imaging program and expressed as the
percentage of responding cells. Video imaging of the calcium-
dependent fluorescence fluxes was also acquired.
2.7. RNA Isolation and Quantitative PCR (qPCR) Analysis.
1 𝜇g of total RNA, extracted with TRI Reagent (Ambion, Life
Technologies), was reverse transcribed using Transcriptor
First Strand cDNA Synthesis Kit for RT-PCR following the
indications of the manufacturer (Roche). Real-time PCR was
conducted with SYBR Green (Roche) on a MyiQ Real-Time
PCR System (Bio-Rad). The TaqMan probes for mouse EP1,
EP2, EP3, EP4, P2Y2, and P2Y4 used in this study were
purchased from Applied Biosystems and experiments for
validation of amplification efficiencywere performed for each
TaqMan probe set [28, 29]. PCR thermocycling parameters
were 95∘C for 10min, 40 cycles of 95∘C for 15 s, and 60∘C
for 1min. Each sample was run in duplicate and was nor-
malized with the expression of 36B4. The fold induction (FI)
was determined in a ΔΔCt based fold-change calculations
(relative quantity, RQ, is 2−ΔΔCt).
2.8. Preparation of Total Protein Cell Extracts and Western
Blot Analysis. Cells were homogenized in a buffer containing
10mMTris-HCl, pH 7.5; 1mMMgCl
2
, 1 mMEGTA, 10% glyc-
erol, 0.5% CHAPS, 1mM 𝛽-mercaptoethanol, and a protease
and phosphatase inhibitor cocktail (Sigma).The extracts were
vortexed for 30min at 4∘C and after centrifuging for 15min
at 13,000×g, the supernatants were stored at −20∘C. Protein
levels were determined with Bradford reagent (Bio-Rad).
For immunoblot analysis the protein extracts were analyzed
as described using a Charged Coupling Device camera in
a luminescent image analyzer (Molecular Imager, BioRad)
to ensure the linearity of the band intensities. Values of
densitometry were determined using Quantity One software
(Bio-Rad).
2.9. MEFs Migration in Transwells. Migration assays were per-
formed in 24 transwells (uncoated 8𝜇m porous transwells)
according to themanufacturer’s instructions (Corning Incor-
porated, NY). 5 × 104 MEFs were seeded in the upper cham-
bers and cells were allowed to attach for 2 h. After thorough
washing with PBS to remove nonadherent cells, MEFs were
starved overnight. Cells were stimulated with combinations
of the indicated stimuli (PGE
2
andUTP in the upper chamber
and 10%FBS,UTP, or PGE
2
into 500𝜇L in the lower chamber,
used as chemoattractants). The plates were incubated at
37∘C overnight in the presence of 20𝜇g/mL of mitomycin C
(Sigma-Aldrich) to inhibit cell proliferation. The membrane
was fixed with paraformaldehyde (4%; pH 7.2) and stained
with crystal violet solution (Sigma-Aldrich). The number of
cells that migrated completely through the 8𝜇m pores was
determined.
2.10. Statistical Analysis. The values in graphs correspond to
themean± SD.The statistical significance was estimated with
a Student’s 𝑡-test for unpaired observation. Data were ana-
lyzed by the SPSS forWindows statistical package, version 21.
3. Results
3.1. Transgenic Expression of COX-2 Impairs P2Y-Dependent
Ca2+-Mobilization. MEFs expressing COX-2 release PGE
2
in the absence of additional stimuli. This accumulation was
enhanced after proinflammatory stimulationwith a combina-
tion of LPS, TNF-𝛼, IL-1𝛽, and IFN-𝛾 (Figure 1(a)). In addi-
tion to this, the presence of PGE
2
inhibited UTP-dependent
Ca2+-mobilization in MEF cells, either when this PG is
exogenously added or when produced by the COX-2 trans-
gene (Figure 1(b)). A video imaging of the Ca2+-transients in
COX-2 WT and KI (expressing the COX-2 transgene) MEFs
treated with different stimuli (PGs and UTP) is shown in
Supplementary Figure S1 in SupplementaryMaterial available
online at http://dx.doi.org/10.1155/2014/832103. Interestingly,
when the medium of COX-2 KI MEFs is replaced by fresh
medium containing the selective COX-2 inhibitor DFU (a
coxib), the impaired P2Y signaling in response to UTP
observed in the same cells without medium change was
abolished (Figure S1). Analysis of the pathways involved
in the impairment of P2Y-dependent Ca2+-mobilization in
MEFs from WT and COX-2 transfected cells (KI) showed
a similar pattern of responses between both conditions
for exogenous PGE
2
or when COX-2 was inhibited with
DFU (Figure 2). The UTP mobilization of Ca2+ was similar
between MEFs from WT or COX-2-deficient mice (data not
shown), regardless of the treatment with DFU. In addition
to this, a broad inhibitor of PKCs and some tyrosine kinases
(staurosporine) partially rescued the response to UTP in KI
cells. Interestingly, inhibition of novel PKCs (𝛿, 𝜀, 𝜂, and 𝜃)
[30] and PKD (Go¨6976 and CID755376, resp.), but not of the
classic isoforms of PKC (𝛼, 𝛽, and 𝛾; inhibited with Go¨6983),
restored the response to UTP in the presence of PGE
2
due
to the activity of COX-2. Opposite to this, activation of
PKCs/PKDwith the diacylglycerol analogue PDBu abolished
the UTP-dependent Ca2+-mobilization, whereas the inactive
phorbol𝛼-PDDwas unable to influence the responses of both
types of cells. PKA activation after treatment with a permeant
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Figure 1: PGE
2
released inMEFs overexpressingCOX-2 and effect onP2Y-dependentCa2+-mobilization.WTandKI (COX-2-deficientMEFs
overexpressing COX-2) MEFs, treated in the absence or presence of LPS (200 ng/mL) plus cytokines (IFN-𝛾, TNF-𝛼, and IL-1𝛽, 20 ng/mL),
were used. The protein levels of COX-1 and COX-2 and the PGE
2
released into the culture medium were determined by immunoblot and
ELISA, respectively (a). The percentage of cells showing Ca2+-mobilization in response to the P2Y agonist UTP (100 𝜇M) was determined
using the nonratiometric Fluo-4 assay (b). Results show a representative blot (a) and the mean + SD of three experiments for release of PGE
2
to the culture medium and Ca2+-mobilization. ∗𝑃 < 0.05, ∗∗𝑃 < 0.001 versus the corresponding control.
cAMP analogue (dibutyril-cAMP) was also unable to affect
UTP signaling (Figure 2). Together, these results suggest that
novel PKCs and PKD are involved in the suppressive effect of
PGE
2
on UTP-dependent Ca2+-mobilization.
3.2. Transgenic Expression of COX-2Accumulates P2Y4 Recep-
tors in the Nucleus. To identify mechanisms involved in the
impairment of P2Y signaling the distribution of these recep-
tors in MEF cells constitutively synthesizing PGE
2
was ana-
lyzed. As Figure 3 shows, P2Y2, P2Y4, and P2Y6were present
in these cells; however, a significant proportion of P2Y4
receptors localized in the nucleus, a situation that was sup-
pressed after inhibition of COX-2 with DFU. This was also
observed in WT MEFs treated with PGE
2
(Supplementary
Figure S2). Interestingly, the expression of EP1–4 PGE
2
recep-
tors and P2Y2 and P2Y4 receptors was not influenced by the
ectopic expression of COX-2 (Figures 4(a) and 4(b)). To
further investigate the effect of PGE
2
on Ca2+-mobilization,
treatment of KI MEFs with the Ca2+ ionophore ionomycin
resulted in identical calcium fluxes regardless of the incuba-
tion with DFU or PGE
2
(Figure 4(c)). Indeed, the shape of
the Ca2+ fluxes exhibited similar profiles when the extracellu-
lar Ca2+ concentration was maintained high (0.5mM) or low
(0.1mM). However, Ca2+-mobilization in response to thapsi-
gargin (i.e., after inhibition of the replenishment of the ER
stores) was significantly inhibited in the presence of PGE
2
(Figure 4(d)). This latter condition was similar to the mobi-
lization induced by thapsigargin in KI cells in the absence of
medium replacement (i.e., with accumulation of PGE
2
in the
culture medium, not shown).
3.3. Thapsigargin-Dependent Phosphorylation inMEFs. To eval-
uate the effect of PGE
2
on Ca2+-mobilization, cells were
treated with prostaglandin and immediately with thapsigar-
gin. As Figure 5(a) shows, the phosphorylation of AKT was
inhibited by PGE
2
and to lesser extents in a proinflammatory
situation. Similar results were obtained for the phosphoryla-
tion of CaMKII and ACC, whereas AMPK phosphorylation
was minimally affected by PGE
2
. These data suggest a com-
plex pattern of phosphorylation of these enzymes beyond
P2Y activation, as previously described in macrophages [20].
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Figure 2: Characterization of targeting of PKC, PKD, and PKA
on the effect of PGE
2
on the UTP-dependent Ca2+-mobilization.
WT or KI MEFs were washed with fresh medium and maintained
in culture for 1 h to remove PGE
2
accumulated and then treated
for 10min with the indicated effectors, except for DFU that was
added immediately afterwashing (1 𝜇MDFU, an inhibitor of COX-2;
5 𝜇M PGE
2
; 100 nM staurosporine; 100 nM Go¨6976; 5 𝜇M Go¨6850;
10 nM Go¨6983, a selective inhibitor of classic PKCs; 200 nM PDBU;
200 nM 𝛼PDD; 200 nM CID755376, a selective inhibitor of PKD;
5 𝜇M dibutyryl cAMP) and the percentage of cells showing Ca2+-
mobilization in response toUTP (100 𝜇M)was determined using the
nonratiometric Fluo-4 assay. Results show the mean + SD of three
experiments for Ca2+-mobilization. ∗𝑃 < 0.05, ∗∗𝑃 < 0.001 versus
the same condition in the WT cells.
3.4. PGE
2
Inhibits P2Y-Dependent Cell Migration. MEFs
migration is affected by extracellular nucleotides [31]. As
Figure 5(b) shows, transwell migration analysis of MEFs
carrying a COX-2 transgene and maintained in the presence
of DFU showed a response that was increased in cells treated
with UTP, a process that was attenuated after pretreatment
with PGE
2
. Interestingly, when PGE
2
was present in both
the upper and lower compartments, cell migration was
completely abolished stressing the effect of this prostaglandin
in the regulation of MEFs motility.
4. Comment
Extracellular nucleotides, such as UTP, have been described
as innate immune regulators acting via the P2 receptors [32,
33]. Indeed, P2 agonists are increasingly viewed as a new class
of innate immune systemmediators following their release at
sites of inflammation as a result of infection or cell damage
[34]. Indeed, interplay between PGs and P2Y response in the
context of macrophage activation, polarization, and resolu-
tion of the inflammation has been described [20]. However,
less is known regarding the role of P2Y receptors and PGE
2
in
other cell types. For this reason, in this work, we provide new
data on the fine regulation of P2Y signaling in MEFs using a
specific agonist. Since fibroblasts play a role in the immune
response [35], our data suggest that MEFs may play a central
role in the regulation in the proresolution and tissue repair
phase [36].
We have characterized the expression of P2Y2, P2Y4,
and P2Y6 in MEFs, using functional and immunological
approaches. Experiments were performed in MEFs from the
WT and COX-2-deficient animals, carrying a COX-2 trans-
gene. The release of PGE
2
impaired UTP-dependent Ca2+-
mobilization responses that could be attributed to the accu-
mulation of PGE
2
in the culture medium. These data clearly
establish a regulation of P2Y receptors by PGE
2
in MEF cells,
in addition to other cells such as macrophages [20]. Interest-
ingly enough, in the intact animal, this PGE
2
can be derived
by several COX-2 expressing cells acting in a concerted way.
Moreover, it has been described that P2X7 receptor activation
is required for the release of PGE
2
in macrophages [37]
which in turn could regulate P2Y responses. Taking this into
account, it seems that there is a complex crosstalk between P2
receptors and PGE
2
release.
All of the cloned P2Y receptors activate phospholipase C
resulting in IP3 generation and Ca2+ release from intracellu-
lar stores. However, the response of the P2Y receptors is regu-
lated bymechanisms involving desensitization that comprises
phosphorylation of the receptors by protein kinases such
as protein kinase C (PKC), attenuating receptor signaling
[38]. Moreover, previous studies have demonstrated that
P2Y receptors desensitization has been attributed to PKC-
dependent mechanisms [39, 40]. In the present work, we
have provided evidence for the involvement of PGE
2
, through
PKC, in P2Y receptor desensitization, analyzing Ca2+ mobi-
lization as read-out. We elucidated the main PKC isoenzyme
responsible for the alterations of Ca2+mobilization by choos-
ing selective PKC inhibitors [30]. As controls, we used PGE
2
and DFU, a selective COX-2 inhibitor which restores the
UTP response, as in MEF WT and in KI cells, suggesting
the regulation of P2 receptors signaling by PGE
2
. Also, we
used Go¨6976, for inhibiting the classic PKC isoforms, and
Go¨6850 that is structurally similar to the poorly selective PKC
inhibitor staurosporine. Go¨6850 shows high selectivity for
PKC𝛼, 𝛽1, 𝛽2, 𝛾, 𝛿, and 𝜀 isoenzymes [41]. Go¨6983 is a pan-
PKC inhibitor against PKC𝛼, 𝛽, 𝛾, and 𝛿. Moreover, phorbol
12,13-dibutyrate (PDBu), a potent activator of PKC/PKD, and
𝛼-phorbol didecanoate (𝛼PDD), which is an inactive derivate
of PDBu, supported the role of these kinases in the regulation
of P2Y activity by PGE
2
. Furthermore, PKDs regulate diverse
cellular processes such as P2 signaling [26]. Previous data
described that activation of PKC𝛿 acts as an upstream PDK1
activation step [42]. For this reason, we use a selective PKD1
inhibitor, CID755376. Taken together, these data indicate that
activation of PKC/PKD reduced Ca2+-mobilization by UTP.
Using selective PKC and PKD inhibitors we hypothesized a
key role for PKCs, although we cannot determine the specific
isoforms involved in the alteration of Ca2+-mobilization by
PGE
2
after stimulation with UTP. The absence of effect after
treatment with dibutyryl-cAMP indicates that the inhibition
by PGE
2
is independent of PKA.These conclusions agreewith
previous evidence describing a regulation of P2Y signaling by
PGE
2
[20]. Our data also indicate that the EP1–4 and P2Y
receptors expression was not influenced by COX-2 activity.
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protocol as described in Section 2. MEFs KI were washed with fresh medium to remove PGE
2
accumulated and maintained in the absence
or presence of 1𝜇MDFU and 5𝜇M PGE
2
. Different extracellular concentrations of calcium were used. Results show the mean + SD of three
experiments (a-b) or a representative trace (c-d). ∗𝑃 < 0.05 versus the same condition in WT cells.
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Figure 5: Effect of thapsigargin on Ca2+-mobilization and migration of MEFs in response to UTP and chemotactic stimuli. WT or COX-2
KI cells were activated, or not, for 24 h with LPS (200 ng/mL) plus cytokines (IFN-𝛾, TNF-𝛼, and IL-1𝛽, 20 ng/mL) and then treated for 5min
with 500 nM thapsigargin and in the absence or presence of 5𝜇M PGE
2
. The levels of the indicated phosphoproteins were determined by
Western blot (a). The capacity of these cells to migrate in transwell was determined after incubation with 5𝜇M PGE
2
and/or 100 𝜇M UTP.
The migration was measured after 24 h of incubation in the absence or presence of different combinations of 10% FBS, PGE
2
(5𝜇M), or UTP
(100 nM) in the lower wells (b). Results show a representative blot (a) out of three or the mean + SD of four experiments (b). ∗𝑃 < 0.05;
∗∗
𝑃 < 0.001 versus the same condition in the absence of treatment in the upper chamber.
Interestingly, PGE
2
did not affect Ca2+ fluxes by ionomycin
but suppressed the effect of thapsigargin, suggesting that
PGE
2
alters Ca2+-mobilization from intracellular stores.
PGE
2
promotes an internalization of P2Y4 in MEFs
transfected with COX-2, an effect that is suppressed after
inhibition of COX-2 with DFU. Based on these results,
we hypothesize that the alteration in Ca2+-mobilization in
response to UTP in MEFs transfected with COX-2 might be
due to a lower membrane localization of P2Y4 when PGE
2
production is enhanced. Moreover, the blockade in Ca2+-
mobilization by PGE
2
has an important reflect in terms of
activation of different signaling pathways, including key reg-
ulators such as PKCs and energetic metabolism via AMPK
activation and ACC inhibition.
Cell migration contributes to normal development and
differentiation. Evidences in recent years have indicated that
extracellular nucleotides can regulate the movement of “pro-
fessional phagocytes” (macrophages, neutrophils, lympho-
cytes, and microglia) and other cell types (e.g., fibroblasts,
endothelial cells, neurons, and keratinocytes) [43]. From a
functional point of view, our data demonstrate that PGE
2
inhibits P2Y-dependent cell migration, regardless of chemo-
attractant.These observations are in agreement with Koizumi
et al. and other authorswhodescribed that P2Y2,4,6 receptors
participate in chemotactic actions [44]. In this way, recent
studies have focused on stromal cells, such as macrophages
and fibroblasts, playing a role in the inflammatory lesion.
Here we describe a cross-regulation between PGE
2
and P2Y
signaling that is independent of the PG receptors in MEFs.
This mechanism is similar to that described by Trave´s et al.
[20], suggesting that macrophages and fibroblasts contribute
to the regulation of inflammatory response and repair of
tissue damage through aligned mechanisms involving P2Y
signaling [35, 36]. Overall, the work suggests that targeting
the stromal microenvironment is likely to be an important
strategy for future anti-inflammatory therapies.
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